Clinical trials: FEV1
Pulmonary Disease, Chronic Obstructive
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive…
- Trial name
- ECLIPSE (NCT00292552)
- Testing
- Novel endpoint determination
- Where
- 44 sites in United States, Bulgaria and 10 more
- Volunteers
- 2,747 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
- Trial name
- NCT01023516
- Testing
- AZD9668
- Where
- 66 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00932646
- Testing
- BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Foradil
- Where
- 13 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
COPD
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol…
- Trial name
- NCT03673670
- Testing
- RPL554 Suspension, Tiotropium/olodaterol (Respimat)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Asthma
A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)
This is a randomised, double-blind, placebo-controlled, parallel group study to determine the efficacy of twenty-seven day- repeat inhaled daily doses of GW870086X on forced expiratory volume in 1 second (FEV1).
- Trial name
- NCT01245426
- Testing
- GW870086 2mg, GW870086 4mg, GW870086 1mg
- Where
- 11 sites in Bulgaria, Germany and 1 more
- Volunteers
- 136 people
- Sponsor
- GlaxoSmithKline
COPD
Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol
The purpose of this study is to assess the change in inspiratory capacity and lung function in patients with chronic obstructive pulmonary disease when treated with indacaterol compared to placebo and formoterol.
- Trial name
- NCT00422552
- Testing
- Indacaterol (QAB149)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in…
- Trial name
- NCT01072149
- Testing
- Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Asthma
Investigation Of A New Medication (GW642444) In Asthmatic Patients
This study will evaluate efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat inhaled doses of GW642444.
- Trial name
- NCT00354874
- Testing
- GW642444, salmeterol 50mcg
- Where
- 3 sites in Germany, Sweden
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with persistent asthma
- Trial name
- NCT01070524
- Testing
- CHF 5188 pMDI, Budesonide extrafine pMDI, Seretide(r) Evohaler(r)
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma
This study will investigate the effects of altering the time of day of dosing (morning or evening) with Fluticasone Furoate 100 (FF 100) micrograms (mcg) once daily administered via a dry powder inhaler (DPI) in subjects with…
- Trial name
- NCT01808339
- Testing
- Fluticasone Furoate (FF)
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Flutiform® Compared With Seretide® in the Treatment of COPD
The purpose of this study is to investigate whether flutiform® is effective and safe in the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02195375
- Testing
- Flutiform 500/20 µg BID, Flutiform 250/10 µg BID, Seretide Accuhaler 50/500 µg BID
- Where
- 5 sites in Australia, China and 3 more
- Volunteers
- 923 people
- Sponsor
- Mundipharma Research Limited
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00931385
- Testing
- BI 1744, bi1744, Foradil
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study
The purpose of this study is to determine the efficacy and safety of chronic treatment with inhaled dry powder mannitol in subjects with cystic fibrosis.
- Trial name
- NCT00446680
- Testing
- Mannitol
- Where
- 29 sites in Australia, Ireland and 1 more
- Volunteers
- 340 people
- Sponsor
- Syntara
Asthma, Efficacy
A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma
This study will be a randomised, double-blind, multiple dose (14 days), placebo-controlled, multi-center study to assess efficacy and safety of three dose levels of AZD7594, given once daily by inhalation, in patients with mild…
- Conditions
- Asthma, Efficacy, Safety
- Trial name
- NCT02479412
- Testing
- 800 μg AZD7594 once daily, 250 µg AZD7594 once daily, 58 µg AZD7594 once daily
- Where
- 10 sites in Bulgaria, Germany
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Asthma
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.
- Trial name
- NCT01836471
- Testing
- QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
- Where
- 76 sites in United States, Belgium and 8 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Perennial Allergy
Clinical Effects of Temperature Controlled Laminar Airflow (TLA)
The purpose of this study is to determine whether clean air administered to the breathing zone with Temperature controlled Laminar Airflow (TLA) during night is effective in the treatment of perennial allergic asthma.
- Trial name
- NCT00987064
- Testing
- Temperature controlled Laminar Airflow (Protexo)
- Where
- 2 sites in Sweden
- Volunteers
- 28 people
- Sponsor
- Airsonett AB
Asthma
MGR001 / Advair Diskus Local Equivalence Study in Asthma
The purpose of this study is to determine whether MGR001 is equivalent to Advair Diskus when administered by inhalation in adult asthma patients
- Trial name
- NCT02245672
- Testing
- MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
- Where
- 101 sites in United States
- Volunteers
- 1,128 people
- Sponsor
- Mylan Pharma UK Ltd.
Asthma
A Study to Evaluate the Effect of Repeat Doses of GW870086X in Mild to Moderate Asthmatics
This study will measure the effect of repeat inhaled doses of GW870086X on lung function.
- Trial name
- NCT00945932
- Testing
- GW870086X
- Where
- 8 sites in Germany
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD
Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD
A study multicenter, phase III, randomized, open label study to evaluate the efficacy and safety of a fixed-dose combination of formoterol/fluticasone and salmeterol/fluticasone in patients with moderate-to-severe chronic…
- Trial name
- NCT01393145
- Testing
- Combination Fluticasone /Formoterol 12/250 μg, Seretide Diskus (salmeterol/fluticasone) 50/250 μg
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the safety and efficacy of QVA149 in patients with moderate to severe COPD.
- Trial name
- NCT00570778
- Testing
- indacaterol/glycopyrrolate, indacaterol
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 154 people
- Sponsor
- Novartis Pharmaceuticals